Form 4: Avidity Director Sells Shares, Options in Novartis Merger

Avidity Biosciences Director Jean Jinsun Kim disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger with Novartis AG.

Summary

• Director Jean Jinsun Kim of Avidity Biosciences, Inc. reported the disposal of securities on February 27, 2026.
• The transactions were executed pursuant to the Agreement and Plan of Merger, dated October 25, 2025, among Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, Inc.
• Kim disposed of 6,692 shares of Common Stock.
• Kim also disposed of 97,523 stock options across five different grants.
• The stock options were exchanged for a cash payment equal to the merger consideration of $72.00 per share minus the respective exercise price of each option grant.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for Avidity Biosciences shareholders due to the substantial merger consideration, but it signifies the end of the company's independent public trading.

Positives

• The merger consideration of $72.00 per share indicates a significant premium for Avidity Biosciences shareholders.
• The disposal of in-the-money options for a cash payment (merger consideration minus exercise price) provided a financial benefit to the director.

Negatives

• The disposal of all reported common stock and options by a director signifies the completion or near completion of the company's acquisition, meaning Avidity Biosciences will no longer trade independently.

Future Outlook

The filing indicates the completion of the merger between Avidity Biosciences and Novartis AG, suggesting Avidity Biosciences will cease to be an independent publicly traded entity.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the final stages of the acquisition of Avidity Biosciences by Novartis AG, a common strategy for large pharmaceutical companies to integrate promising biotech assets. This trend reflects the ongoing consolidation in the biopharmaceutical sector, where established players seek to bolster their pipelines through strategic M&A.

Comparison to Industry Standards

• StockSavvy.ai observes that the merger consideration of $72.00 per share for Avidity Biosciences represents a significant premium over its pre-merger trading price, aligning with typical acquisition premiums seen in the biotechnology sector for companies with promising therapeutic platforms.
• Similar acquisitions, such as Gilead Sciences' acquisition of Immunomedics for $21 billion (approximately $88 per share) or Bristol Myers Squibb's acquisition of MyoKardia for $13.1 billion (approximately $225 per share), also demonstrated substantial premiums, reflecting the high value placed on innovative drug candidates and platforms.

Stakeholder Impact

• Shareholders: Receive $72.00 per share for their common stock and cash for in-the-money options, representing a significant return.
• Employees: Avidity Biosciences employees will become part of Novartis AG, potentially impacting roles and corporate culture.
• Customers/Partners: No direct impact mentioned, but Avidity's pipeline will now be integrated into Novartis's broader strategy.

Next Steps

• Completion of the merger process, leading to Avidity Biosciences becoming an indirect wholly-owned subsidiary of Novartis AG.
• Delisting of Avidity Biosciences common stock from public exchanges.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Jean Jinsun Kim